investors.trevena.comInvestor Relations :: Trevena, Inc. (TRVN)
investors.trevena.com Profile
investors.trevena.com
Maindomain:trevena.com
Title:Investor Relations :: Trevena, Inc. (TRVN)
Description：Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions.
Discover investors.trevena.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.trevena.com Information
| Website / Domain: | investors.trevena.com |
| HomePage size: | 35.106 KB |
| Page Load Time: | 0.263566 Seconds |
| Website IP Address: | 52.52.116.221 |
| Isp Server: | E.I. du Pont de Nemours and Co. Inc. |
investors.trevena.com Ip Information
| Ip Country: | United States |
| City Name: | Wilmington |
| Latitude: | 39.749801635742 |
| Longitude: | -75.554298400879 |
investors.trevena.com Keywords accounting
| Keyword | Count |
|---|
investors.trevena.com Httpheader
| Date: Fri, 18 Sep 2020 08:11:26 GMT |
| Server: Apache |
| Expires: Thu, 19 Nov 1981 08:52:00 GMT |
| Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 |
| Pragma: no-cache |
| Set-Cookie: major_announcement=deleted; expires=Thu, 01-Jan-1970 00:00:01 GMT; Max-Age=0 |
| Vary: Accept-Encoding |
| Content-Encoding: gzip |
| Content-Length: 7529 |
| Keep-Alive: timeout=5, max=100 |
| Connection: Keep-Alive |
| Content-Type: text/html; charset=UTF-8 |
investors.trevena.com Meta Info
| charset="utf-8"/ |
| content="ie=edge" http-equiv="x-ua-compatible"/ |
| content="https://www.trevena.com/investors" property="og:url"/ |
| content="Trevena, Inc." property="og:site_name"/ |
| content="Investor Relations" property="og:title"/ |
| content="website" property="og:type"/ |
| content="https://d1io3yog0oux5.cloudfront.net/_65e8e66857634b6ac7d0b9fec7b72d5d/trevena/db/726/5591/social_image_resized.png" property="og:image"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions." property="og:description"/ |
| content="Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions." name="description"/ |
| content="initial-scale=1.0, width=device-width" name="viewport"/ |
| content="#ffffff" name="theme-color"/ |
52.52.116.221 Domains
| Domain | WebSite Title |
|---|
investors.trevena.com Similar Website
| Domain | WebSite Title |
|---|---|
| Investor Relations :: Trevena, Inc. (TRVN) | |
| Trevena, Inc. (TRVN) | |
| Nelnet Inc - Investor Resources - Investor Services Program | |
| Exantas Investor Relations - Investor Overview | |
| Winnebago Investor Relations Investor Home | |
| Universal Technical Institute's Investor Relations - UTI Investor Relations | |
| Choice Hotels International - Investor Relations Home - Investor Relations | |
| Equitable Bank Investor Relations - Investor Relations - Overview | |
| Investor Relations - American Express Investor Relations | |
| 51Talk Investor Relations - Investor Relations Home | |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations | |
| Lankan Investor - Lankan Investor - Home | |
| Investor Relations | Investor Relations | Littelfuse | |
| Matt McCall's Early Stage Investor Account : Matt McCall's Early Stage Investor | |
| 58.com Investor Relations - Welcome |
investors.trevena.com Traffic Sources Chart
investors.trevena.com Alexa Rank History Chart
investors.trevena.com Html To Plain Text
Home About Overview Management Team Board of Directors Pipeline Overview TRV250 TRV734 TRV045 TRV027 Products OLINVYK™ (oliceridine) injection Publications Investors Overview Press Releases Events & Presentations Financial Info Stock Info Resources Governance Contact Overview Careers Investor Relations Investors Investors Overview Press Releases Events & Presentations Presentations IR Calendar Financial Info Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Stock Info Quote Analyst Coverage Resources Email Alerts Contacts FAQ Governance Overview Management Team Board of Directors Governance Documents Latest News Trevena, Inc. to Present at September Virtual Investor Conferences Sep 2, 2020 View Press Release Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine Aug 26, 2020 Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London Aug 24, 2020 View All News Latest Presentation Sep 14, 2020 Corporate Presentation Upcoming Event Sep 23, 2020 • 11:40 am EDT Oppenheimer Fall Healthcare Life Sciences & MedTech Summit View Event Add to Calendar View All Latest Financial Results Q2 2020 Quarter Ended Jun 30, 2020 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Dec 31, 2019 Report Links Annual Report Document Links View 10-K Email Alerts Receive updates straight into your inbox Sign up today Company Overview Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com . The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders. View Management Team View Board of Directors Investor Contact Information Company Trevena, Inc. 955 Chesterbrook Blvd Suite 110 Chesterbrook, PA 19087 T: (610) 354-8840 ir@trevena.com Investor Relations LifeSci Advisors, LLC Dan Ferry Managing Director T: 617-430-7576 daniel@lifesciadvisors.com Email Alerts Tear Sheet Contacts RSS News Feed © 2020 Trevena, Inc. All Rights Reserved. Privacy Policy Terms of Use Disclaimer Sitemap Market Data copyright © 2020 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use ....
investors.trevena.com Whois
"domain_name": "TREVENA.COM",
"registrar": "Network Solutions, LLC",
"whois_server": "whois.networksolutions.com",
"referral_url": null,
"updated_date": [
"2016-04-27 13:29:23",
"2018-02-14 01:23:29"
],
"creation_date": "1997-10-23 04:00:00",
"expiration_date": "2023-10-22 04:00:00",
"name_servers": [
"NS33.WORLDNIC.COM",
"NS34.WORLDNIC.COM"
],
"status": "clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"emails": [
"abuse@web.com",
"dburnip@trevenainc.com"
],
"dnssec": "unsigned",
"name": "Burnip, Dan",
"org": "Trevena, Inc.",
"address": "955 CHESTERBROOK BLVD STE 110 STE 110",
"city": "CHESTERBROOK",
"state": "PA",
"zipcode": "19087-5615",
"country": "US"